China's NMPA Announces 34 New Medical Device Industry Standards
China's National Medical Products Administration announced 34 new medical device industry standards on October 8, 2024. These standards cover various areas including dental materials, blood purification equipment, ophthalmology instruments, surgical implants, AI in medical devices, robotic surgical systems, genetic testing kits, and tissue engineering materials. The standards aim to regulate performance, safety, and quality requirements, reflecting technological advancements in China's medical device industry. Implementation dates range from 2025 to 2027.
China's NMPA Announces Results of Medical Device Quality Inspection (Notice No. 35 of 2024)
The National Medical Products Administration (NMPA) of China has released the results of its latest quality inspection of medical devices. The inspection, covering 17 categories of products, found 24 batches (units) that failed to meet the required standards on September 12, 2024.
Read MoreNMPA to Strengthen Supervision of Medical Device Clinical Trial Institutions
NMPA has approved new measures to enhance the supervision of medical device clinical trial institutions. These measures, effective from October 1, 2024, aim to clarify regulatory responsibilities, standardize inspection procedures, and ensure the protection of trial participants' rights and safety. The initiative emphasizes the importance of trial quality and outcome authenticity. In support, the NMPA will soon release detailed inspection guidelines and conduct training sessions to improve regulatory capabilities.
Read MoreChina's NMPA Reports Five Cases of Illegal Medical Device Sales Online (Batch Six)
On May 31, 2024, the National Medical Products Administration (NMPA) released information about five recent cases of illegal online sales of medical devices. The NMPA has taken stern actions to regulate the online sale of medical devices to protect public health and ensure device safety.
Read MoreNMPA Releases 48 New Guidelines for Medical Device Registration Review
On May 27, 2024, the Center for Medical Device Evaluation (CMDE) of the National Medical Products Administration (NMPA) released 48 new guidelines for the registration review of various medical devices, including electric photography beds. The guidelines cover a wide range of medical device categories, such as diagnostic equipment, therapeutic devices, auxiliary equipment, rehabilitation tools, and in vitro diagnostic reagents. These guidelines aim to standardize the registration process, enhance industry standards, and ensure the safety and effectiveness of medical devices. Detailed guidelines for specific devices, including medical gas alarm systems, air-oxygen blenders, radiotherapy laser positioning devices, and various testing reagents, are provided to support manufacturers in meeting regulatory standards. The full texts of these guidelines are available on the NMPA's official CMDE website.
Read MoreClinical Trial Design Considerations for Single-Port Laparoscopic Surgical Systems for Gynecological Surgery
This article outlines the clinical trial design for assessing the safety and effectiveness of a single-port laparoscopic surgical system in gynecological surgeries. The trial adopts a prospective, single-group design, targeting common high-risk gynecological procedures. Key evaluation metrics include the non-conversion rate and complications graded Clavien-Dindo 3 or higher within 30 days post-operation, alongside secondary endpoints like surgery duration, intraoperative blood loss, patient pain scores, and overall complication rates. With a sample size of 60 cases, determined from expected performance data and dropout rates, the trial covers representative procedures such as radical hysterectomy and comprehensive staging surgery for endometrial cancer. Statistical analysis follows established guidelines to ensure rigorous assessment of the system's efficacy and safety.
Read MoreChina Tightens Medical Device Classification Rules to Enhance Safety and Efficiency
The National Medical Products Administration has issued Announcement No. 59 of 2024 to improve the classification management of medical devices. The announcement details the procedures for classifying medical devices based on regulations and guidelines, focusing on factors like intended use and risks. It covers classification for new devices, uncertain categories, and emergency situations during public health crises. The implementation begins on September 1, 2024, replacing the previous classification notification.
Read MoreRegulatory Requirements for Medical Device Manufacturing and Distribution Under the New IVD Classification Catalogue
The National Medical Products Administration (NMPA) of China has released new guidelines under the "In Vitro Diagnostic Reagent Classification Catalogue" to update the regulatory framework for the manufacturing and distribution of medical devices. These guidelines necessitate that manufacturers and distributors of in vitro diagnostic reagents adhere to specific licensing and registration processes based on the management categories detailed in their product registration certificates. The NMPA has mandated continued use of the classification "Management Category - 6840 In Vitro Diagnostic Reagents" across various scopes of manufacturing and distribution. Additionally, provincial drug regulatory authorities are instructed to facilitate the training and implementation of these new regulations to ensure compliance and enhance the management of medical devices, particularly focusing on in vitro diagnostic reagents. This initiative is part of the NMPA’s broader efforts to streamline and improve regulatory processes within the medical device sector in China.
Read MoreMore Insights into China's Updated Classification Guidelines for In Vitro Diagnostic Reagents
China's NMPA introduced significant updates to the management and classification of in vitro diagnostic reagents. These updates include maintaining the validity of existing registrations approved before this date and requiring new registration applications to comply with a revised classification catalogue. The changes also address category adjustments, where products must re-register under the new or old categories depending on risk level adjustments. Additionally, the NMPA will continue processing renewal and change applications received before the effective date under the old catalogue. Class I in vitro diagnostic reagents have a specific transition period until June 30, 2024, after which they must comply with the new catalogue. These revisions aim to enhance the regulatory framework, ensuring the safety and efficacy of in vitro diagnostic reagents in line with current standards.
Read MoreChina's NMPA Issues New Guidelines for In Vitro Diagnostic Reagent Classification
The National Medical Products Administration (NMPA) of China has released Notification No. 17 of 2024, introducing the "Catalogue of In Vitro Diagnostic Reagent Classification." This initiative is designed to streamline the classification process for in vitro diagnostic reagents as per the "Regulations on the Supervision and Management of Medical Devices" and other related guidelines. The Catalogue delineates the scope and structure of these reagents, excluding those used for legally mandated blood screening and those labeled with radioactive isotopes, and organizes them into a detailed system of 25 first-level and 1,852 second-level categories based on detection targets. It provides a pathway for the management of new products, allowing for direct Class III registration or category determination under the Classification Rules. The notification also specifies the management of various products including culture and cell culture media, and general reagents. Moreover, it announces the repeal of previous related notices, effective January 1, 2025, and highlights the dynamic adjustment of the Catalogue based on ongoing risk analysis and device evaluation. This systematic update aims to ensure regulatory compliance and facilitate the registration and filing processes for in vitro diagnostic reagents.
Read More